Repros Therapeutics Inc. (RPRX)
-NasdaqCM | Prev Close: | 19.19 |
|---|
| Open: | N/A |
|---|
| Bid: | 17.51 x 100 |
|---|
| Ask: | 25.49 x 200 |
|---|
| 1y Target Est: | 26.33 |
|---|
| Beta: | 0.72 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 7.82 - 20.78 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 624,234 |
|---|
| Market Cap: | 357.76M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.41 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: Repros Therapeutics announces proposed public offering of 3 mln shares of common stockBriefing.com(Mon, Jun 17)
- Repros Therapeutics Inc.(R) Announces Proposed Public Offering of Common StockGlobeNewswire(Mon, Jun 17)
- REPROS THERAPEUTICS INC. Files SEC form 8-K, Other EventsEDGAR Online(Mon, Jun 17)
- REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsEDGAR Online(Fri, Jun 7)
- Repros to Webcast Investor and Analyst Day on June 6thGlobeNewswire(Mon, Jun 3)
- REPROS THERAPEUTICS INC. Files SEC form 8-K, Other EventsEDGAR Online(Mon, Jun 3)
- The 5 Dumbest Things on Wall Street This Week: May 31at TheStreet(Fri, May 31)
- Repros to Conduct Phase IIb TrialZacks(Thu, May 23)
- REPROS THERAPEUTICS INC. Files SEC form 8-K, Other EventsEDGAR Online(Wed, May 22)
- FDA Recommends Running Phase 2b Trial of Proellex(R)-V in the Treatment of Severe Menstrual Bleeding Associated With Uterine FibroidsGlobeNewswire(Wed, May 22)
- REPROS THERAPEUTICS INC. FinancialsEDGAR Online Financials(Fri, May 17)
- REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD DisclosureEDGAR Online(Thu, May 16)
- Repros Therapeutics Inc.(R) Reports First Quarter 2013 Financial ResultsGlobeNewswire(Fri, May 10)
- Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarinat TheStreet(Fri, May 10)
- REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Fri, May 10)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.49 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.40 |
|---|
| Mean Recommendation*: | 1.3 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Repros Therapeutics Inc., a development stage biopharmaceutical company, engages in the development of new drugs to treat hormonal and reproductive system disorders.
View More 
0.91%